Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement

Aug

08

Today In Oncology

Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma

When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology

Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer

AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer

WHO Calls for Action in New Status Report on Cancer

Advertisement

© 2026 HSP News Service, L.L.C.